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The possible dependence of human melanoma on endocrine 
influences has been speculated upon for many years. Clinical 
data suggest that females have a better prognosis t han males; 
t h e improved survival in women is irrespective of site of the 
primary lesion or clinical stage [1]. Numerous case reports have 
demonstrated an exacerbation of pre-existing melanomas dur-
ing pregnancy with regression followin g cessation of pregnancy. 
Recently, Shiu et al [2] have shown in a retrospective review of 
fe male melanoma patients that stage I patients with "activa-
tion" of the lesion during pregnancy had the same prognosis as 
women wi thout any such association, bu t stage II pa tients 
(those with regional lymph node metastases) had a significantly 
worse prognosis if the melanoma appeared or flar ed during 
pregnancy when compared to age-matched nulliparous or par-
o us stage II patients without any such "activation ." It t hus 
a ppears from this clinical informat ion that a subset of patients 
with melanoma may have a hormonally responsive tumor. 
Hormonal therapy of disseminated melanoma has been used 
infrequently and is generally regarded as ineffective. However , 
o ne study has noted that a drug with glucocorticoid and ant i-
estrogenic activities, NSC- 17256 (6a-methylpregn-4-ene3,11,20-
t rione) produced objective tumor regressions in 5 of 44 patients 
[3]. Others have reported 2 cases of objective tumor regressions 
following hypophysectomy, one patient who responded to tes-
tosterone, and one who responded to ethinylestradiol [ 4]. Some 
propor tion of patients may, therefore, have tumors which are 
hormonally dependent and are sensitive to endocrine manipu-
la tions. 
ANIMAL EXPERIMENTS 
Several animal models have been studied for possible endo-
crine influences on melanoma. A transplantable melanoma in 
h amsters has been shown to possess a faster initial growth rate 
in females than males, bu t when ovariectomy was performed at 
t h e time of t umor transplantation this difference was no longer 
apparent [5]. Lipkin has shown that in vitro growth of another 
transplantable hamster melanoma was inhibited by pharma-
cologically relevant concentrations of either testosterone or, to 
a lesser extent, estradiol; in vivo, the tumor grew more rapidly 
and resulted in shorter survival in females t han in males [6]. 
Thus, these experimental findings may bear some relationship 
to th e above noted human da ta and suggest the possibility t hat 
some melanoma may be hormonally sensit ive. 
MECHANISM OF STEROID HORMONE ACTION 
temperature dependent activation step which permits nuclear 
t ranslocation and presumed binding to specific nucleru· sites. 
Transcription of specific DNA segments ensues with appru·en t 
regula tion at least at t he level of t he primary mRNA transcript. 
The mRNA produced is processed, t ransported to t he cyto-
plasm, and eventually t ranslated into specific proteins, th e end 
product of steroid action. These protein products ar e felt to be 
responsible for a ll of t he phenotypic effects of steroids. Thus, 
although the presence of a cytoplasmic receptor appears to be 
a necessru·y prerequisite for t he steroid to exer t its specific 
mechanism of action, t he presence of the receptor need not 
necessarily signify hormonal responsiveness. This has been 
clearly demonstrated in patients with metastatic breast cancer, 
where only 60 to 70% of patients whose tumors contain estrogen 
receptor activity respond to endocrine manipulation [7]. 
STEROID HORMONE BINDING IN HUMAN 
MELANOMA 
The clinical and experimental data described above led to 
our preliminary investigations reported in 1976 [8.9]. Using a 
dextran-coated ch ar coal assay, separate estrogen, progesterone, 
glucocorticoid, and androgen binding activi ties were evaluated 
in a series of 35 patients. Estrogen binding activity was detected 
in 45%, progesterone binding activity in 22 %, androgen binding 
activity in 17%, and glucocorticoid binding activity in 19%. The 
amount of estrogen binding activity was generally low (w hen 
compared to breast cancer ) with the highest value being 91 
fem tomoles/mg of cytosol protein. Nevertheless, many of the 
dissociation constants obtained by Scatchard analysis were in 
the range previously observed in breast cancer a nd in other 
endocrine responsive t issues. In 2 cases with estrogen binding 
activity where enough tumor tissue was available to perform 
specificity studies, the binding of 3H-estradiol was competed for 
only by compounds with estrogenic or anti-estroo-enic activit ies· 
thus, the binding of estradiol noted in melano~a appeared t~ 
be similar in specificity to the estrogen receptor activity noted 
in breast cancer. Unfortunately, sucrose density gradient anal-
yses were not performed to compare sedimentation character-
istics to those found in other estrogen target t issues. We con-
cluded from this small series t hat melanoma appeared to bind 
steroid hormones in a manner similar to that found in endo-
crine-responsive tissues and tumors and we hypothesized t hat 
these investigations might allow selection of a subset of patients 
whose tumors might r espond to endocrine therapy. 
Since our preliminary observations we have extended our 
Different classes of steroid hormones are thought to exe rt series to 111 patien ts and others have also investigated hormone 
their speciJic effects on cells th1·ough similar mechanisms. Cell binding in patients with melanoma. 
membranes are freely permeable to steroid hormones. Once ' Estrogen binding activi ty has been analyzed in all 111 pa-
inside the cell the steroid binds to an intrace llular protein (the tients. This assay has been validated both by its predictive 
" receptor") . The receptor-steroid complex t hen undergoes a accuracy in metastatic breast cancer [10] and by comparison 
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with resul ts obta ined with reference powders. Twenty-four 
patients had estrogen binding activity with values ranging fro m 
4 to 91 fmols/mg of cytosol protein; only 9 patients had values 
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greater than 20 and only 1 greater than 50. Dissociation con-
stants (K0 ) ranged from 0.147 to 8.15 nM; only 3 were greater 
than 3 nM. Specific binding of the labeled estradiol was inhibited 
by 17 ,8-estradiol, diethylstilbestrol, and tamoxifen, all com-
pounds which bind to the estrogen receptors demonstrated in 
other tissues; significant competition was not observed at up to 
2000-fold molar excesses of 17a-estradiol, dihydrotestosterone, 
progesterone, testosterone, or cortisol. Migration on sucrose 
density grad ients in 2 cases showed 4S peaks, bu t we have been 
unable to detect a defini te 8S peak. The presence of binding 
activity did not correlate with sex, site, or stage of disease. 
Several other groups have assayed smaller numbers of pa-
tients for specific estrogen binding activi ty . Creagan eta! (per-
sonal communication) , at the Mayo Clinic, assayed 38 mela-
noma specimens in 34 patients; 4 patients had estrogen binding 
activity noted but the values were only 3,3,4 and 5 fmol/mg of 
cytosol protein. The patient with a value of 5 fmoljmg had 2 
subsequent biopsies that were negative. Kokoschka and col-
leagues found that 15% of 41 melanomas were estrogen receptor 
positive. He also noted that 81% were androgen receptor posi-
tive and claimed all to be progestin receptor positive [11]. 
Chaudhur i and his colleagues (personal communication) , at the 
University of Illinois, found estrogen binding activity in 10 of 
27 (37%) patients; their values also tended to be low and their 
dissociation constants were in the range of 0.1 to 1 nM. On 
sucrose density gradients only 4S activity has been detected. It 
is of interest that they also investigated benign nevi; no nevi 
from 15 patients without melanoma contained estrogen binding 
activity, but 9 of 22 benign nevi from patients with melanoma 
did contain estrogen binding activity [12]. The significance of 
this is unclear, but it is possible that melanocytes that contain 
estrogen binding activity may be "activated" and may be pre-
malignant. 
We have also investigated binding activity for other steroid 
hormones in melanoma. Progesterone binding was detected in 
18 of 85 (21 %) patients; the values ranged from 11 to 320 fmol/ 
mg of cytosol protein (3 values were greater than 50 fmol/mg) 
with dissociation constants of 0.45 to 18 nM (only 2 values were 
larger than 6 nM). Androgen binding activity was present in 11 
of 71 (15%) patients; concentrations were very low, ranging 
from 4.7 to 57.9 fmol/mg of cytosol protein, only 4 greater than 
15 fmol/mg. Dissociation constants ranged from 0.3 to 30 nM. 
Glucocorticoid binding activity was found in 18 of 65 (28%) 
patients with values from 10 to 300 fmol/mg of cytosol protein 
and dissociation constants of about 2 to 5 nM. When these 
values are compared to the values usually seen in breast cancer 
or other receptor containing, endocrine-responsive tissues the 
binding capacities are quite low bu t the dissociation constants 
are similar. Clearly, high affinity binding data are not equivalent 
to demonstration of true receptors. Detailed specificity studies, 
sucrose density gradient behavior, nuclear translocation, and 
association with hormonal response would all tend to suggest 
that these binding activities might be true receptors. The 
limited specificity studies for estrogen binding activity are 
similar to those noted in endocrine responsive tissues, bu t other 
specificity data are not yet available. Finally, sucrose density 
gradient analysis both in our laboratories and by others has not 
yet demonstrated the patterns observed in breast cancer, uter-
ine tissue, or other steroid-hormone responsive tissues. It does 
appear, however, that high affinity, limited capacity binding for 
4 classes of steroid hormones may be found in human mela-
noma. 
TISSUE CULTURE OBSERVATIONS 
Human melanoma cells being grown in long term tissue 
cul ture may offer an opportunity to correlate the presence or 
absence of steroid hormone binding activi ty with responsiveness 
to endocrine th erapy. We have investigated 21 melanoma cell 
lines and have been unable to detect estrogen binding activity; 
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of the 5 cell lines tested to date for estrogen responsiveness, 
none have demonstrated any effect of estrogenic or anti-estro-
genic compounds on aH -thymidine or 14 C-leucine incorporation. 
Chaudhuri et al [13] have reported that 4 of 6 melanoma cell 
lines contained estTOgen binding activity with values ranging 
from 62.7 to 238 fmol/mg cytosol protein and dissociation 
constan ts from 0.3 to 4 nM. Progesterone binding activity was 
present in 3 of 6 cell lines and no androgen binding activity was 
detected. Cell lines that contained specific binding appeared to 
be responsive (as measured by increase in celt numbers) to 
physiologic concentrations of the appropriate steroid; cell lines 
lacking such binding showed no response to steroid hormone 
administration. These data have not yet been confir med with 
other cell lines (Neifeld JP, unpublished observations). 
Beattie et a! [14] have investigated the effect of sex on the 
growth of melanoma in nude mice. They compared one cell line 
that contained estrogen binding activi ty (ER+) to one that did 
not (ER-) for growth after transplantation into nude mice. The 
ER- line exhibited increased latency when compared to the 
ER+ line, but there was no difference in tumor incidence or 
growth in males. The ER- cell line grew faster in females than 
did the ER+ cell line. In other work from th e sam e laboratory 
[15], estradiol decreased tumor take in the estrogen binding cell 
line and latency was increased, although there was no effect of 
estradiol on tumor growth. They interpreted these observations 
as being consistent with estrogen-inhibiting growth of the ER+ 
cell lines. They felt this was consistent with the more favorable 
prognosis of melanoma in women [16]. This work has yet to be 
confirmed by other investigators. 
CLINICAL CORRELATIONS 
The initial reports describing steroid hormone receptors in 
melanoma (vide supra) and suggesting their presence migh t 
indicate endocrine responsiveness have led to several clinical 
studies. At the Natio nal Cancer Institute 35 patients with 
measurable disease have been treated with diethylstilbestrol 
(15 mg/ day). There were 2 objective responses (5.7%), but 
neither patient's tumor contained estrogen binding. Meyskens 
(personal communication), at the University of Arizona, has 
treated 11 patients with T amoxifen 20 mg/day. One patient 
had a complete response and 3 had partial responses (>50% 
regression of tumor). Estrogen binding analyses were not per-
formed. Creagan et al (personal communication) have treated 
25 patients with measurable, advanced disease by administering 
T amoxifen 40 mg/day. No patient had an objective 1·esponse 
although 2 patients did have less than 50% regressions of tumor. 
The median time to progression was about 30 days and median 
sw·vival was about 100 days. In a recently reported trial, one of 
15 evaluated patients achieved a partial regression of soft tissue 
disease with medroxyprogesterone acetate (500 mg/day) [1 7]. 
Steroid binding assays were not reported. Thus, these stud ies 
suggest that few patients with metastatic melanoma, even if 
t heir tumors might contain steroid hormone binding activity, 
will be responsive to endocrine manipulation. 
DISCUSSION 
The apparent discrepancy between the presence of specific 
steroid hormone binding in human melanoma and lack of 
substantial response rates to endocrine therapy is intriguing. 
There are several possible explanations which require fu ture 
study. First, as suggested above, the presence of steroid hor-
mone receptors does not necessarily signify steroid hormone 
responsiveness. There may be defects in translocation of recep-
tor, transcription, translation, or, in fact, the growth and repli-
cation of melanoma cells may be independent of an intact 
steroid hormone pathway. 
A second possibility is that the steroid binding represents 
binding to either an inactive receptor or another protein present 
in some melanomas. Although binding constants and specifici-
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t ies appear similar to those noted in endocrine responsive 
t umors and normal tissues, t he pattern of migration on sucrose 
d e nsity gradients has not yet been shown to contain an 8S peak. 
S ince the basic genetic "machinery" in a ll cells is the same, 
d e repression of the chromat in segment that codes for steroid 
h o rmone binding activity could result in synthesis of a receptor 
(or portion of a receptor) t ha t has no biological significance. 
The objective response to steroid hormones by tumors that 
lack specific binding is also of great inte rest. This may be due 
to tec hnical errors in the assay. It could also be due to an 
indirect effect of the steroid on tumor growth. For example, 
estrogens are known to affect the activity of MSH (as well as 
gonadotrophins, prolactin, glucocorticoids, etc. ), a nd thJ·ough 
s u ch an effect the apparent inhibition (or stimulation) of tumor 
growth could occm. Another possibili ty might be that the 
hormone effec t could be mediated through some intracellular , 
n o nTeceptor mechanism. Currently, experiments in our and 
other laboratories are investigating these possibiMies. 
CONCLUSIONS 
Although several tentative conclusions may be tendered re-
garding steroid hormone receptors and melanoma, it must be 
remembered that only a small number of pa tients have been 
investigated and tha t these statements may change as more 
d a ta become available: 
1. Retrospective studies suggest a small subset of patients 
with melanoma may have tumors responsive to steroid hor-
mones. 
2. The da ta from several centers suggest that a small per-
centage of patients have tumors that contain specific high 
a ffini ty, limited capacity binding for steroid hormones. 
3. The presence (or absence) of steroid hormone binding 
activity in melanoma has not been shown to correlate with in 
v ivo (and possibly in vitro) responses to endocrine manipula-
tion. 
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